### Analysis

The earnings call for Merck & Co., Inc. revealed a solid performance in the third quarter of 2012, despite the impact of the SINGULAIR patent expiration and other headwinds. The company maintained revenue and EPS growth, highlighting the strength of its core products and geographic expansion. Management expressed confidence in its strategy and pipeline, with several key products expected to drive growth in the coming years.

### Conclusion

The stock is likely to experience a positive impact in the short term, driven by the company's strong performance, pipeline advancements, and strategic initiatives. However, the stock may face some volatility due to the patent expiration of SINGULAIR and the uncertainty surrounding the upcoming launches of new products.

### Rating

1